Description and Brand Names

Drug information provided by: IBM Micromedex

US Brand Name

  1. Adakveo

Descriptions


Crizanlizumab-tmca injection is used to prevent vaso-occlusive crisis in patients with sickle cell disease. Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is blocked by sickled red blood cells and may lead to organ damage.

This medicine is to be given only by or under the direct supervision of your doctor.

This product is available in the following dosage forms:

  • Solution

Portions of this document last updated: Feb. 01, 2020

Copyright © 2020 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

See also

  1. Adalimumab-Afzb (Subcutaneous Route)
  2. Cenobamate (Oral Route)
  3. Cysteine (Intravenous Route)
  4. Dermatophagoides Farinae Extract And Dermatophagoides Pteronyssinus Extract (Subcutaneous Route)
  5. Elexacaftor, Tezacaftor, Ivacaftor And Ivacaftor (Oral Route)
  6. Enfortumab Vedotin-Ejfv (Intravenous Route)
  7. Givosiran (Subcutaneous Route)
  8. Glyburide, Micronized (Oral Route)
  9. Golodirsen (Intravenous Route)